PyInvesting

Market research

BIO Bio-Rad Laboratories Inc

NYSE USD Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
10B
P/E ratio
46.29
Analyst target
329
Dividend yield
Not available
Beta
1.05

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

Bio-Rad Laboratories, Inc is currently in a long term uptrend where the price is trading 13.5% above its 200 day moving average.

From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.0.

Bio-Rad Laboratories, Inc's total revenue rose by 26.5% to $790M since the same quarter in the previous year.

Its net income has increased by 51.6% to $839M since the same quarter in the previous year.

Finally, its free cash flow grew by 77.6% to $245M since the same quarter in the previous year.

Based on the above factors, Bio-Rad Laboratories, Inc gets an overall score of 5/5.